Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Doug Linn"'
Autor:
Yun Wang, Long Cui, Peter Georgiev, Latika Singh, Yanyan Zheng, Ying Yu, Jeff Grein, Chunsheng Zhang, Eric S. Muise, David L. Sloman, Heidi Ferguson, Hongshi Yu, Cristina St. Pierre, Pranal J Dakle, Vincenzo Pucci, James Baker, Andrey Loboda, Doug Linn, Christopher Brynczka, Doug Wilson, Brian B Haines, Brian Long, Richard Wnek, Svetlana Sadekova, Michael Rosenzweig, Andrew Haidle, Yongxin Han, Sheila H. Ranganath
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Prostaglandin E2 (PGE2), an arachidonic acid pathway metabolite produced by cyclooxygenase (COX)-1/2, has been shown to impair anti-tumor immunity through engagement with one or more E-type prostanoid receptors (EP1-4). Specific targeting of EP recep
Externí odkaz:
https://doaj.org/article/36e7a55740434d6e88a502ce5e86b72a
Autor:
Milind D. Chalishazar, Nicolas Solban, Johnny Kopinja, Doug Linn, Razvan Cristescu, Heather Zhou, Thomas Rosahl, Brian Long, Weisheng Zhang, Eric Hostetler
Publikováno v:
Cancer Research. 82:2455-2455
Immunotherapy has revolutionized the way cancer is treated; however, despite tremendous success, not all patients benefit from immunotherapy. Identifying biomarkers predictive of effective treatment response to current and novel immunotherapies is of
Autor:
Yun, Wang, Long, Cui, Peter, Georgiev, Latika, Singh, Yanyan, Zheng, Ying, Yu, Jeff, Grein, Chunsheng, Zhang, Eric S, Muise, David L, Sloman, Heidi, Ferguson, Hongshi, Yu, Cristina St, Pierre, Pranal J, Dakle, Vincenzo, Pucci, James, Baker, Andrey, Loboda, Doug, Linn, Christopher, Brynczka, Doug, Wilson, Brian B, Haines, Brian, Long, Richard, Wnek, Svetlana, Sadekova, Michael, Rosenzweig, Andrew, Haidle, Yongxin, Han, Sheila H, Ranganath
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Prostaglandin E2 (PGE2), an arachidonic acid pathway metabolite produced by cyclooxygenase (COX)-1/2, has been shown to impair anti-tumor immunity through engagement with one or more E-type prostanoid receptors (EP1-4). Specific targeting of EP recep
Autor:
My Sam Mansueto, Brooke M Swalm, Patrick S. Fier, Rachel L. Palte, Sandra Lee, Kristin Geddes, Josep Saurí, Michael H. Reutershan, Charles S. Yeung, Benjamin Nicholson, David J. Witter, Murray Wan, Robert P Hayes, Haiyan Xu, David L. Sloman, Nicole Follmer, Daniel S. Spellman, Danica A. Rankic, Pierre Daublain, Timothy J. Henderson, Jongwon Lim, Dapeng Chen, Erik Munsell, Guo Feng, Steven M. Silverman, Ryan V Quiroz, Doug Linn, Sulagna Sanyal, Michelle R. Machacek, Craig R. Gibeau, Shuhei Kawamura, Yuanwei Gao, Jonathan M E Hughes, Sebastian Schneider, Phieng Siliphaivanh, Yingchun Ye, Brian M. Lacey
Publikováno v:
Journal of medicinal chemistry. 64(7)
Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the post-translational symmetric dimethylation of protein substrates. PRMT5 plays a critical role in regulating biological processes including transcr
Autor:
Latika Singh, Pranal J Dakle, Eric S. Muise, Heidi Ferguson, Cristina St. Pierre, Yanyan Zheng, James Baker, Chunsheng Zhang, Brian Long, Hongshi Yu, Brian B. Haines, Christopher Brynczka, Doug Linn, Vincenzo Pucci, Michael Rosenzweig, Jeff Grein, Sheila Ranganath, Andrew M. Haidle, Richard Wnek, Peter Georgiev, Svetlana Sadekova, Yongxin Han, Ying Yu, Long Cui, Andrey Loboda, Doug Wilson, Yun Wang, David L. Sloman
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Prostaglandin E2 (PGE2), an arachidonic acid pathway metabolite produced by cyclooxygenase (COX)-1/2, has been shown to impair anti-tumor immunity through engagement with one or more E-type prostanoid receptors (EP1-4). Specific targeting of EP recep